Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

Status unconfirmed · Phase 4

Conditions studied: Sentinel Lymph Node Biopsy, Breast Cancer

In brief

A randomized controlled double-blinded study comparing the intraoperative injection of lymphatic mapping agents Tc 99m tilmanocept to Tc 99m filtered sulfur colloid in breast cancer patients undergoing breast conservation and sentinel lymph node biopsy

Key facts

Study ID

NCT03199560

Run by

Memorial Health University Medical Center

People needed

86

Starts

2017-06-22

Expected to finish

2019-08-22

Last updated by the study team

2018-08-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women above 18 years of age with biopsy proven, clinically stage 1 or 2 breast cancer who will be undergoing partial mastectomy with SLNBx at Memorial Health

You may not qualify if…

• Women under the age of 18,
• Clinically positive axillary nodes
• Neoadjuvant therapy for current breast cancer diagnosis
• Women with previous SLNBx or axillary node dissection
• Pregnant women
• Women with previous radiation above the diaphragm, and below the neck

Where it is running

• Memorial Health University Medical Center — Savannah, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.